Payment overview · 2025
General Payments
$1,413.57
35 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Wayne Yorek, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATON ROUGE, LA · NPI 1225030737
Verified facts
What the public records show
CMS Open Payments records show Michael Wayne Yorek, M.D. received $1,413.57 in general payments during 2025 across 35 reported records.
Abbott Laboratories accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $351.63 | 24.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $244.07 | 17.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.64 | 14.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.25 | 11.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$167.21 | 11.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.68 | 8.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.33 | 3.2% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.44 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.83 | 2.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.04 | 1.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.36 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.09 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,413.57 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $351.63 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $168.25 | 4 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $167.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $154.98 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $154.98 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.27 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.33 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.22 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 126 |
| Metformin Hcl Er | Metformin Hcl | 338 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 72 |
| Losartan Potassium | Losartan Potassium | 206 | 60 |
| Lisinopril | Lisinopril | 205 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 53 |
| Ezetimibe | Ezetimibe | 148 | 43 |
| Montelukast Sodium | Montelukast Sodium | 145 | 39 |
| Alprazolam | Alprazolam | 144 | 24 |
| Sertraline Hcl | Sertraline Hcl | 136 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 36 |
| Allopurinol | Allopurinol | 130 | 32 |
| Gabapentin | Gabapentin | 129 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 30 |
| Meloxicam | Meloxicam | 112 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 28 |
| Ozempic | Semaglutide | 107 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 24 |
| Memantine Hcl | Memantine Hcl | 103 | 21 |
| Omeprazole | Omeprazole | 99 | 31 |
| Simvastatin | Simvastatin | 99 | 21 |
| Liothyronine Sodium | Liothyronine Sodium | 98 | 26 |
| Furosemide | Furosemide | 95 | 31 |
| Metformin Hcl | Metformin Hcl | 94 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 25 |
| Celecoxib | Celecoxib | 91 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 27 |
| Glimepiride | Glimepiride | 89 | 25 |
| Potassium Chloride | Potassium Chloride | 82 | 22 |
| Jardiance | Empagliflozin | 80 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 18 |
| Donepezil Hcl | Donepezil Hcl | 78 | 25 |
| Mirtazapine | Mirtazapine | 78 | 19 |
| Januvia | Sitagliptin Phosphate | 74 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 60 |
| Pregabalin | Pregabalin | 70 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Tramadol Hcl | Tramadol Hcl | 68 | 31 |
| Famotidine | Famotidine | 64 | 16 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Buspirone Hcl | Buspirone Hcl | 62 | 14 |
| Fenofibrate | Fenofibrate | 57 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Clonazepam | Clonazepam | 56 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Eliquis | Apixaban | 51 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Acarbose | Acarbose | 46 | 15 |
| Dexamethasone | Dexamethasone | 46 | 40 |
| Finasteride | Finasteride | 44 | 13 |
| Methocarbamol | Methocarbamol | 44 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Linzess | Linaclotide | 43 | 11 |
| Doxepin Hcl | Doxepin Hcl | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Valsartan | Valsartan | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Ramipril | Ramipril | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Carvedilol | Carvedilol | 32 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 31 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,413.57 · 35 records | Abbott Laboratories | BREZTRI, COREVALVE EVOLUT R, CREON, FREESTYLE LIBRE 3, Fluad, Flucelvax, INJECTAFER, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Veozah, XYOSTED, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error